Salvage surgery or salvage radiotherapy for locally recurrent prostate cancer

被引:28
作者
Tefilli, MV
Gheiler, EL
Tiguert, R
Banerjee, M
Forman, J
Pontes, JE
Wood, DP
机构
[1] Wayne State Univ, Dept Urol, Sch Med, Detroit, MI 48201 USA
[2] Wayne State Univ, Dept Radiat Oncol, Sch Med, Detroit, MI 48201 USA
[3] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
关键词
D O I
10.1016/S0090-4295(98)00151-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To evaluate the efficacy and toxicity of salvage radiation or surgery for locally recurrent tumor after initial treatment for clinically localized prostate cancer. Methods. The treatment records of 70 patients with local treatment failure after definitive therapy for clinically localized prostate cancer were reviewed. Initial treatment consisted of external beam radiation therapy (RT) in 27 patients and radical retropubic prostatectomy (RP) in 43 patients. Results. The mean serum PSA levels were similar in both groups before initial treatment: 8.5 and 10.5 ng/mL for the salvage RP and salvage RT groups, respectively (P = 0.09). However, at the time of salvage treatment, the mean serum PSA levels were 9.1 and 1.1 ng/mL for the salvage RP and salvage RT groups, respectively (P = 0.0001). The mean time from tumor recurrence to salvage treatment was 15.6 months for the salvage RP group and 4.9 months for the salvage RT group (P = 0.0001). Although there was no statistical difference in the disease-free survival rate (P = 0.38), a trend for better disease control in the salvage RT group was evident (74.4% versus 44.4%). Patients treated with salvage RP had a higher rate of urinary incontinence than those undergoing salvage RT: 63% and 32.6%, respectively (P = 0.01). Conclusions. The disease-free survival rate was similar between patients receiving salvage RP or RT, despite the significantly higher serum PSA levels at the time of treatment and the delay in time to treatment for the salvage RP patients. Salvage RP is associated with a high rate of urinary incontinence. Earlier identification of tumor recurrence after RT may improve the efficacy and safety of salvage RP. UROLOGY 52: 224-229, 1998. (C) 1998, Elsevier Science Inc. All rights reserved.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 31 条
  • [11] IDENTIFICATION OF RESIDUAL CANCER IN THE PROSTATE FOLLOWING RADIATION-THERAPY - ROLE OF TRANS-RECTAL ULTRASOUND GUIDED BIOPSY AND PROSTATE SPECIFIC ANTIGEN
    KABALIN, JN
    HODGE, KK
    MCNEAL, JE
    FREIHA, FS
    STAMEY, TA
    [J]. JOURNAL OF UROLOGY, 1989, 142 (02) : 326 - 331
  • [12] PROSTATE-SPECIFIC ANTIGEN FOR PRETREATMENT PREDICTION AND POSTTREATMENT EVALUATION OF OUTCOME AFTER DEFINITIVE IRRADIATION FOR PROSTATE-CANCER
    KUBAN, DA
    ELMAHDI, AM
    SCHELLHAMMER, PF
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (02): : 307 - 316
  • [13] LANGE PH, 1989, J UROLOGY, V141, P873
  • [14] Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival
    Lee, WR
    Hanlon, AL
    Hanks, GE
    [J]. JOURNAL OF UROLOGY, 1996, 156 (02) : 450 - 453
  • [15] CRITICAL-EVALUATION OF SALVAGE SURGERY FOR RADIO-RECURRENT RESISTANT PROSTATE-CANCER
    LERNER, SE
    BLUTE, ML
    ZINCKE, H
    [J]. JOURNAL OF UROLOGY, 1995, 154 (03) : 1103 - 1109
  • [16] SALVAGE SURGERY FOLLOWING RADICAL RADIOTHERAPY FOR ADENOCARCINOMA OF THE PROSTATE
    MADOR, DR
    HUBEN, RP
    WAJSMAN, Z
    PONTES, JE
    [J]. JOURNAL OF UROLOGY, 1985, 133 (01) : 58 - 60
  • [17] EVALUATION OF SERUM PROSTATE-SPECIFIC ANTIGEN VELOCITY AFTER RADICAL PROSTATECTOMY TO DISTINGUISH LOCAL RECURRENCE FROM DISTANT METASTASES
    PARTIN, AW
    PEARSON, JD
    LANDIS, PK
    CARTER, HB
    POUND, CR
    CLEMENS, JQ
    EPSTEIN, JI
    WALSH, PC
    [J]. UROLOGY, 1994, 43 (05) : 649 - 659
  • [18] PARTIN AW, 1993, UROL CLIN N AM, V20, P713
  • [19] THE CLINICAL USEFULNESS OF PROSTATE-SPECIFIC ANTIGEN - UPDATE-1994
    PARTIN, AW
    OESTERLING, JE
    [J]. JOURNAL OF UROLOGY, 1994, 152 (05) : 1358 - 1368
  • [20] PONTES JE, 1994, UROL CLIN N AM, V21, P701